Adults who are overweight or obese and currently using semaglutide (Ozempic®/Wegovy®) or tirzepatide (Mounjaro®/Zepbound®) may qualify for a research study evaluating an investigational weight loss medication.
Obesity Study
Age Range:
18
Gender:
Male and Female
Location:
Rochester, New York
About the Study
This research study is evaluating maridebart cafraglutide, an investigational medication designed to help maintain weight loss in adults who have previously responded to GLP-1 treatment. The study medication is given as an injection using a prefilled syringe.
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of switching from a currently prescribed GLP-1 medication to the investigational study medication.
Qualifications
You may be able to join if you:
- Are 18 years of age or older
- Have a BMI greater than 25 kg/m²
- Have used semaglutide or tirzepatide consistently for at least 6 months
- Have maintained a stable dose of your medication for at least 6 months
- Have lost at least 10% of your body weight while using semaglutide or tirzepatide
- Have had stable body weight over the past 6 months
FEATURED STUDIES
An upcoming clinical research study is evaluating an investigational treatment designed to help prevent the flu in adults who may […]
An upcoming clinical research study is evaluating an investigational vaccine designed to help prevent illness caused by norovirus in adults […]
An upcoming clinical research study is evaluating an investigational long-acting approach designed to help prevent influenza. Join our interest list […]
Adults 65 and older may qualify for a clinical research study evaluating an investigational seasonal flu vaccine.
This clinical trial will help us learn if receiving another dose of the RSV vaccine is safe and can help […]
Adults 18 years and older may qualify for a study evaluating an investigational oral study medication for elevated lipoprotein(a) [Lp(a)], […]